Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

4.0K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
4.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

2.0K
The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-Wide Association Study for Glucocorticoid-Induced Ocular Hypertension.

Ophthalmology science·2026
Same author

Utilization and Costs Among Bladder Cancer, Other Cancer, and Noncancer Populations in the United States.

Urology·2026
Same author

Association between hyperphosphatemia and overall survival among patients with advanced urothelial cancer treated with erdafitinib in phase 2/3 clinical trials.

Cancer·2026
Same author

Outcome Differences Between Subgroups of Favorable Intermediate Risk Prostate Cancer After Radical Prostatectomy.

The Prostate·2026
Same author

Association between prostate cancer and mental health: a comparison across cancer types using the medical expenditure panel survey, 2017-2022.

Journal of cancer survivorship : research and practice·2026
Same author

Testicular Cancer Survivorship and Prostate Cancer-New Questions on Risk and Outcomes.

The Prostate·2026

Related Experiment Video

Updated: Jan 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.

Trevor C Hunt1, Kamil Malshy1, Matthew Steidle1

  • 1Department of Urology, University of Rochester Medical Center, Rochester, New York, USA.

The Prostate
|September 10, 2025
PubMed
Summary

Testosterone recovery after androgen deprivation therapy (ADT) did not impact survival outcomes for men with high-risk prostate cancer (HRPCa) undergoing radical prostatectomy. This finding suggests flexibility in treatment strategies for HRPCa patients.

Keywords:
androgen deprivation therapyevent‐free survivaloncologyoverall survivalradiation therapyurology

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

677
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.0K

Related Experiment Videos

Last Updated: Jan 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

677
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.0K

Area of Science:

  • Oncology
  • Urology
  • Endocrinology

Background:

  • Prostate cancer (PCa) is androgen-sensitive, leading to androgen deprivation therapy (ADT).
  • High-risk PCa (HRPCa) outcomes are worse than low-risk disease.
  • Testosterone recovery post-ADT impacts outcomes in radiation-treated patients, but not in surgically managed HRPCa.

Purpose of the Study:

  • To investigate the association between testosterone recovery and oncologic outcomes in HRPCa patients treated with radical prostatectomy (RP) and ADT.
  • To explore if the speed of testosterone recovery influences outcomes.

Main Methods:

  • Retrospective analysis of pooled data from two phase III clinical trials (CALGB 90203 and SWOG S9921).
  • Inclusion of 445 HRPCa patients treated with ADT and RP.
  • Classification of patients into testosterone recovered or non-recovered groups based on predefined thresholds; analysis of early vs. late recovery.

Main Results:

  • 87.2% of patients achieved testosterone recovery.
  • No significant differences in overall survival (OS) or modified event-free survival (mEFS) between recovered and non-recovered groups.
  • No significant differences observed when analyzing data per trial or by speed of recovery (early vs. late).

Conclusions:

  • Testosterone recovery status and speed are not significantly associated with oncologic outcomes in HRPCa patients post-RP and ADT.
  • Findings support further research into treatment strategies like intermittent ADT for HRPCa.
  • Results may inform quality of life optimization while maintaining cancer efficacy.